UBS lowered the firm’s price target on Terns Pharmaceuticals to $18 from $19 and keeps a Buy rating on the shares. UBS thinks Terns is underappreciated, with Phase 1 updates in chronic myeloid leukemia and obesity expected in the second half of this year, both of which could have opportunities in large markets, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TERN:
- Terns Pharmaceuticals price target lowered to $15 from $17 at JMP Securities
- Terns Pharmaceuticals reports Q4 EPS (29c), consensus (29c)
- Terns Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates
- Terns Pharmaceuticals receives orphan drug designation for TERN-701 from FDA
- Terns Pharmaceuticals Announces Orphan Drug Designation Granted to TERN-701 for the Treatment of Chronic Myeloid Leukemia
